Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up

Tohru Nakagawa, Masahiro Kami, Akiko Hori, Sung Won Kim, Naoko Murashige, Tamae Hamaki, Yukiko Kishi, Hiroyuki Fujimoto, Naoki Matsuoka, Eijiro Okajima, Motokiyo Komiyama, Ken Ichi Tobisu, Toshio Wakayama, Naokuni Uike, Kinuko Tajima, Atsushi Makimoto, Shinichiro Mori, Ryuji Tanosaki, Yoichi Takaue, Tadao Kakizoe

研究成果: Article

37 引用 (Scopus)

抜粋

Objective The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen (RIST) for interferon-α-refractory metastatic renal cell carcinoma (RCC). Patients and methods Of 26 patients referred to the National Cancer Center Hospital for possible RIST between June 2000 and April 2002, an HLA-identical relative was identified for 12 patients. Nine patients underwent RIST. The conditioning regimen consisted of fludarabine 180 mg/m 2 or cladribine 0.66 mg/kg, plus busulfan 8 mg/kg and rabbit antithymocyte globulin 5 mg/kg. Graft-vs-host disease (GVHD) prophylaxis was cyclosporine alone. Results All patients achieved engraftment without grade III to IV nonhematologic regimen-related toxicity. All patients achieved complete donor-type chimerism without donor lymphocyte infusion by day 60. Four patients developed acute GVHD, and four developed chronic GVHD. One patient (11%) achieved partial response. As of July 2003, six patients were alive at median follow-up of 681 days. The actuarial overall survival rate was 89% at 1 year and 74% at 2 years. The overall survival rate tended to be higher in the 12 patients with a matched donor than in the other 14 patients without a matched donor (p=0.088). Conclusion Our RIST procedure is feasible without severe toxicity. The efficacy of RIST for RCC should be confirmed in phase II/III clinical trials.

元の言語English
ページ(範囲)599-606
ページ数8
ジャーナルExperimental Hematology
32
発行部数7
DOI
出版物ステータスPublished - 2004 7 1
外部発表Yes

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

フィンガープリント Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Nakagawa, T., Kami, M., Hori, A., Kim, S. W., Murashige, N., Hamaki, T., Kishi, Y., Fujimoto, H., Matsuoka, N., Okajima, E., Komiyama, M., Tobisu, K. I., Wakayama, T., Uike, N., Tajima, K., Makimoto, A., Mori, S., Tanosaki, R., Takaue, Y., & Kakizoe, T. (2004). Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up. Experimental Hematology, 32(7), 599-606. https://doi.org/10.1016/j.exphem.2004.04.006